Vertex Pharmaceuticals Inc (VRTX)

215.01
+1.85(+0.87%)
After Hours
214.47
-0.54(-0.25%)
- Real-time Data
  • Volume:
    1,232,048
  • Bid/Ask:
    213.55/216.55
  • Day's Range:
    213.81 - 216.77

VRTX Overview

Prev. Close
213.16
Day's Range
213.81 - 216.77
Revenue
6.41B
Open
214.36
52 wk Range
202.57 - 306.08
EPS
10.51
Volume
1,232,048
Market Cap
55.66B
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
1,842,223
P/E Ratio
20.28
Beta
0.67
1-Year Change
-20.37%
Shares Outstanding
258,865,671
Next Earnings Date
Jul 28, 2021
What is your sentiment on Vertex Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Vertex Pharmaceuticals Inc News

Vertex Pharmaceuticals Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyBuySellNeutral
Technical IndicatorsStrong BuyStrong BuyStrong BuySellSell
SummaryStrong BuyStrong BuyStrong BuySellNeutral

Vertex Pharmaceuticals Inc Company Profile

Vertex Pharmaceuticals Inc Company Profile

Employees
3400

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Read More
  • Give the anti-corona spray from marinomed-biotech some VC and invest in a pharma company which is heading to the moon:https://www.investing.com/equities/marinomed-biotech-agStudies are proving that the patented method of marinomed prevents infection with all Corona varietis including mutants. It also prevents other virus infections. They have many patents.  Do some good and get rich
    3
    • hopefully reach 230 @Earning
      1
      • Very resilient to drop!
        0
        • It will reach $ 240 dollars today
          1
          • VRTX $231.71 @ Close (Earnings)
            0
            • Ark buying large
              1
              • when will be the next earning ? By then price will easy gain 20,%
                0
                • 2/01/2021
                  0
              • After withdrawing out of the Covid vaccine race it had a large drop, but then, once that factor was discounted by the markets and after beating earnings expectations I wonder why does it keep falling ... any idea?
                4
                • Vertex was not in covid vaccine race, drop was on another reason
                  0
              • what happen to this stock lately? it should go to $270 very easily
                0
                • This Should b @ $300 @ $75B Valuation But not @ $54B @ $215 & $12B Cash by Next year, $6-7B Revenue
                  0
                  • I covered my stocks, a big crash it's coming
                    0
                    • Looks like you missed the biggest 3 days in trading thus far..... a side from the Late Aug rally.
                      0
                  • Analyst ratings for this stock are near $300, but i dont know what is going on with it
                    0
                    • Anybody know why the ***it is down $3?
                      0
                      • lately good news makes them drop... none of it makes sense lately, unless it's people just cashing out..
                        0
                      • If so, 207 is a poor place to close a position on this stovk.
                        0
                    • Negative sentiment (election, COVID) seems to be dragging everything down. Equities are like hot potatoes.
                      0
                      • So why the price is not moving??
                        0
                        • it even went down
                          0
                      • One of my best stocks
                        0
                        • EPS: $2.53 act. vs. 2.32 forecastREV. $1.54B act. vs. 1.48 forecast
                          0
                          • Two beats. They are now saying adj EPS $2.64
                            0
                        • UBS initiated coverage with a buy. Price target $287. We'll see what earnings bring.
                          0
                          • expectations for next week?
                            0
                            • it is on 29th oct.
                              1
                              • i checked. it is on 29th oct.
                                0
                                • i checked. it is on 29th oct.
                                  0
                                  • Where are the earnings? Wasn’t it today?
                                    0
                                    • i checked. it is on 29th oct.
                                      0
                                    • i checked. it is on 29th oct.
                                      0
                                    • Yeah. ***website, I sold because of them!
                                      0
                                  • will level out around 200 until the pause it's over
                                    0
                                    • it starts hurting me. hmm
                                      0
                                      • haha why
                                        0
                                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.